# Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure

> **NCT03273322** · PHASE2,PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 105 (actual)

## Conditions studied

- Atrial Fibrillation
- Atrial Appendage
- Hemorrhage

## Interventions

- **DRUG:** Rivaroxaban 10 mg qd
- **DRUG:** Rivaroxaban 15 mg qd
- **DRUG:** DAPT

## Key facts

- **NCT ID:** NCT03273322
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-13
- **Primary completion:** 2018-11-20
- **Final completion:** 2019-09-30
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2021-12-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03273322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03273322, "Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03273322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*